140 related articles for article (PubMed ID: 36254284)
1. Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer.
van Delft FA; Schuurbiers M; Muller M; Burgers SA; van Rossum HH; IJzerman MJ; Koffijberg H; van den Heuvel MM
Heliyon; 2022 Oct; 8(10):e10932. PubMed ID: 36254284
[TBL] [Abstract][Full Text] [Related]
2. Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.
van Delft FA; Schuurbiers MMF; Muller M; Burgers SA; van Rossum HH; IJzerman MJ; van den Heuvel MM; Koffijberg H
Tumour Biol; 2024; 46(s1):S269-S281. PubMed ID: 37545289
[TBL] [Abstract][Full Text] [Related]
3. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer.
Muller M; Hoogendoorn R; Moritz RJG; van der Noort V; Lanfermeijer M; Korse CM; van den Broek D; Ten Hoeve JJ; Baas P; van Rossum HH; van den Heuvel MM
Tumour Biol; 2021; 43(1):115-127. PubMed ID: 34219680
[TBL] [Abstract][Full Text] [Related]
4. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.
Molina R; Auge JM; Escudero JM; Marrades R; Viñolas N; Carcereny E; Ramirez J; Filella X
Tumour Biol; 2008; 29(6):371-80. PubMed ID: 19060513
[TBL] [Abstract][Full Text] [Related]
5. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
8. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer.
Pang L; Wang J; Jiang Y; Chen L
Exp Ther Med; 2013 Aug; 6(2):355-360. PubMed ID: 24137188
[TBL] [Abstract][Full Text] [Related]
9. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG; Abbati F; Facchinetti F; Massucci M; Melotti B; Squadrilli A; Buti S; Formica F; Tiseo M; Ardizzoni A
Ther Adv Med Oncol; 2020; 12():1758835920952994. PubMed ID: 33193825
[TBL] [Abstract][Full Text] [Related]
10. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
Clevers MR; Kastelijn EA; Peters BJM; Kelder H; Schramel FMNH
Anticancer Res; 2021 Feb; 41(2):869-876. PubMed ID: 33517292
[TBL] [Abstract][Full Text] [Related]
12. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
14. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
15. Cross-Sectional Study to Establish the Utility of Serum Tumor Markers in the Diagnosis of Lung Cancer.
Mehta A; Parkash A; Bhatia M
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2569-2576. PubMed ID: 34452572
[TBL] [Abstract][Full Text] [Related]
16. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer.
Yoshimura A; Uchino J; Hasegawa K; Tsuji T; Shiotsu S; Yuba T; Takumi C; Yamada T; Takayama K; Hiraoka N
Transl Lung Cancer Res; 2019 Jun; 8(3):227-234. PubMed ID: 31367536
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors.
Molina R; Filella X; Augé JM; Fuentes R; Bover I; Rifa J; Moreno V; Canals E; Viñolas N; Marquez A; Barreiro E; Borras J; Viladiu P
Tumour Biol; 2003; 24(4):209-18. PubMed ID: 14654716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
